Postoperative Pulmonary ComplicationsSupAIRNCT07829094
Postoperative Pulmonary Complications After Use of Supraglottic Airway Devices and Neuromuscular Blockade
A study testing Airway management strategy, Initiation of neuromuscular blockade (NMB) and Deep versus moderate neuromuscular blockade (NMB) in people with Postoperative Pulmonary Complications, run by University Hospital Ulm.
Trial summary
SupAIR is an international, multicenter, randomized controlled trial investigating whether airway management and neuromuscular blockade during general anesthesia influence postoperative pulmonary complications. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Postoperative Pulmonary Complications
- What is being tested?
- Airway management strategy, Initiation of neuromuscular blockade (NMB) and Deep versus moderate neuromuscular blockade (NMB)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6,800 participants
- Where
- No sites listed yet
- Study dates
- 15 Oct 2026to 1 Sep 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients (≥ 18 years) with an ASA physical status ≤ 3 scheduled for elective non-cardiac surgery under general anaesthesia whose airway can be secured via tracheal tube or SGA.
Who cannot join
- Contraindications for using supraglottic devices, tracheal tube, or neuromuscular blocking agents (and reversal drugs); surgery in prone positioning; surgical procedures scheduled outside the operating room; ambulatory surgery; pregnancy; patients planned for consecutive anaesthetic/surgical procedures in the following 14 days or within the past 14 days.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Béla-Simon Paschold, M.D. Coordinating Investigator contact
Clinical Research Physician contact
About this study
SupAIR is an international, multicenter, randomized controlled trial investigating whether airway management and neuromuscular blockade during general anesthesia influence postoperative pulmonary complications.
Approximately 6,800 adults undergoing elective non-cardiac surgery will be randomized to one of five treatment arms: tracheal intubation with moderate neuromuscular blockade, tracheal intubation with deep neuromuscular blockade, supraglottic airway with moderate neuromuscular blockade, supraglottic airway with deep neuromuscular blockade, or supraglottic airway without neuromuscular blockade.
The primary outcome is the occurrence of postoperative pulmonary complications during the hospital stay. Secondary outcomes include perioperative complications, surgical conditions, recovery, and functional health. Participants will be followed during hospitalization and again approximately six months after surgery.
Read the detailed description
SupAIR is an international, multicenter, randomized, controlled, parallel-group clinical trial evaluating the effects of airway management and neuromuscular blockade (NMB) on postoperative pulmonary complications after general anesthesia.
A total of 6,800 adults undergoing elective non-cardiac surgery will be randomized to one of five treatment arms:
- Tracheal tube with moderate NMB
- Tracheal tube with deep NMB
- Supraglottic airway device with moderate NMB
- Supraglottic airway device with deep NMB
- Supraglottic airway device without NMB
The five treatment arms result from an initial allocation to tracheal tube with NMB, supraglottic airway device with NMB, or supraglottic airway device without NMB. Participants assigned to NMB are additionally randomized to moderate or deep neuromuscular blockade.
The study addresses two primary hypotheses. First, among participants receiving NMB, use of a supraglottic airway device is hypothesized to reduce postoperative pulmonary complications compared with tracheal intubation. Second, among participants managed with a supraglottic airway device, the use of NMB is hypothesized not to increase postoperative pulmonary complications compared with no NMB. Finally, among participants receiving NMB depth of neuromuscular blockade will be used as secondary exposure.
The randomized intervention determines airway management and the use and depth of neuromuscular blockade. Quantitative neuromuscular monitoring is used in participants receiving NMB, and recovery from neuromuscular blockade is managed according to applicable clinical guidelines. All other aspects of perioperative anesthetic management are performed according to local clinical practice.
The primary outcome is the occurrence of at least one postoperative pulmonary complication from postoperative day 1 until hospital discharge or postoperative day 28, whichever occurs first. The composite includes respiratory failure, suspected pulmonary infection, pulmonary infiltrates, atelectasis, aspiration pneumonitis, bronchospasm, and pulmonary oedema.
Postoperative outcomes are assessed by blinded study personnel during the hospital stay. Secondary outcomes include intraoperative and postoperative complications, respiratory events in the post-anesthesia care unit, surgical conditions, quality of recovery, functional health, length of stay, intensive care treatment, and mortality. Participants are additionally followed by telephone approximately six months after surgery.
An interim analysis is planned after approximately 1,000 participants to assess assumptions relevant to sample-size planning. Interim results will be reviewed by the independent Data and Safety Monitoring Board, and the total sample size may be adjusted in accordance with the prespecified analysis plan.
- Conditions
- Postoperative Pulmonary Complications
- Being tested
- Airway management strategy, Initiation of neuromuscular blockade (NMB), Deep versus moderate neuromuscular blockade (NMB)
- Keywords
- Postoperative Complications, Laryngeal Masks, Intubation, Endotracheal Tube, Neuromuscular Blockade, Surgical conditions, Postoperative pulmonary complications, PPC, Anesthesia, Supraglottic airway
- Medical subject headings
- Postoperative Complications
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Airway management strategyProcedure or surgery
For the superiority hypothesis the placement of the supraglottic airway device compared to the endotracheal tube is investigated.
Initiation of neuromuscular blockade (NMB)Procedure or surgery
For the non-inferiority hypothesis the initiation of neuromuscular blockade in patients receiving a supraglottic airway is investigated.
Deep versus moderate neuromuscular blockade (NMB)Other
Deep or moderate NMB. Muscle relaxants are administered according to group allocation. Repetitive doses of half the ED95s are administered at Train-of-Four (TOF) count ≥ 2 in the moderate group and at post-tetanic count (PTC) ≥ 2 in the deep blockade group.
| Study group | Role | What they receive |
|---|---|---|
| Tracheal Tube with moderate Neuromuscular Blockade (TT/moderate NMB) | Active comparator | General anesthesia with tracheal tube management and moderate neuromuscular blockade. Receives: Procedure: Airway management strategy; Other: Deep versus moderate neuromuscular blockade (NMB) |
| Supraglottic Airway Device with deep Neuromuscular Blockade (SGA/deep NMB) | Experimental | General anesthesia with supraglottic airway device management and deep neuromuscular blockade. Receives: Procedure: Airway management strategy; Procedure: Initiation of neuromuscular blockade (NMB); Other: Deep versus moderate neuromuscular blockade (NMB) |
| Supraglottic Airway Device without Neuromuscular Blockade (SGA/no NMB) | Active comparator | General anaesthesia with supraglottic airway device management without neuromuscular blockade. Receives: Procedure: Initiation of neuromuscular blockade (NMB) |
| Tracheal Tube with deep Neuromuscular Blockade (TT/deep NMB) | Active comparator | General anesthesia with tracheal tube management and deep neuromuscular blockade. Receives: Procedure: Airway management strategy; Other: Deep versus moderate neuromuscular blockade (NMB) |
| Supraglottic Airway Device with moderate Neuromuscular Blockade (SGA/moderate NMB) | Experimental | General anesthesia with supraglottic airway device management and moderate neuromuscular blockade. Receives: Procedure: Airway management strategy; Procedure: Initiation of neuromuscular blockade (NMB); Other: Deep versus moderate neuromuscular blockade (NMB) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Occurrence of at least one postoperative pulmonary complication
The primary outcome is a composite endpoint of postoperative pulmonary complications. It is met if a participant experiences at least one predefined postoperative pulmonary complication and their severity is graded according to the Clavien-Dindo-Classification
Measured: Postoperative day one until hospital discharge or postoperative day 28, whichever occurs earlier
Secondary outcomes (7)
Intraoperative complications
The classification of intraoperative adverse events (ClassIntra), ranging from grade 0 to grade V. It is used to assess intraoperative anaesthesia- and surgery-related complications.
Measured: During the surgery
Critical respiratory events in the recovery room
The outcome is met if at least one predefined critical respiratory event occurs. Events include upper airway obstruction requiring intervention, hypoxaemia not responding to active interventions, signs of respiratory distress or impending ventilatory failure, inability to breathe deeply, symptoms of respiratory or upper-airway muscle weakness, suspected pulmonary aspiration, or reintubation.
Measured: During post-anesthesia care before admission to the normal ward
Any postoperative in-hospital complication
Postoperative complications are recorded during the hospital stay during predefined visits in accordance with the postoperative morbidity survey including pulmonary, infectious, renal, gastrointestinal, cardiovascular, neurological, hematological, wound and pain). If a complication occurs each complication is categorized according to the Clavien-Dindo classification.
Measured: Patients are visited on postoperative days 1 and 3 to 4 in person and on the day of discharge from hospital or day 28 (whatever occurs first) via chart review to document complications between the current and the last assessment.
Surgical conditions
Surgical conditions will be assessed in a single-blinded manner via the Leiden Surgical Rating Scale which ranges from 1 to 5, with 1 indicating extremely poor surgical conditions and 5 indicating optimal surgical conditions considering visibility, surgical space, muscle contractions, handling tactics and patient movement.
Measured: During surgery, assessed every 15 minutes
Quality of Recovery questionnaire
The Quality of Recovery 15 questionnaire will be assessed and consists of 15 items to determine subjective recovery after surgery on an 11-point Likert scale (0-10) summing to a maximum of 150 points with greater sum representing better recovery.
Measured: On postoperative day 1, day of discharge or on day 28 whatever occurs first and on postoperative day 180
Functional Health
The WHODAS-2 (World Health Organization Disability Assessment Schedule 2.0) scale will be used to quantify the level of disability ranging from 0 (no difficulty) to 42 (great difficulty) within the last 30 days.
Measured: During pre-admission testing and 180 days after surgery
Further Outcomes
Length of hospital stay, length of intensive care unit stay and 180-day mortality.
Measured: Retrieved from Chart Review or at the 180 day follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2026
- Study start15 Oct 2026 (estimated)
- Primary completion1 Sep 2029 (estimated)
- Study completion1 Sep 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Postoperative Pulmonary ComplicationsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a randomized, controlled, parallel-group trial with three study groups. Participants are allocated to tracheal tube management with neuromuscular blockade (TT/NMB), supraglottic airway device management with neuromuscular blockade (SGA/NMB), or supraglottic airway device management without neuromuscular blockade (SGA/no NMB). Allocation occurs in an unequal ratio of 1:2.9:2.9. Patients receiving NMB are additionally allocated 1:1 to receive either deep or moderate neuromuscular blockade.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 6,800 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital Ulm
- Sponsor type
- University, hospital or other
- Collaborators
- Medical University of Vienna, Universitätsmedizin Mannheim, Klinikum Oldenburg gGmbH, University Hospital, Zürich, St. Josef Hospital Bochum
- Responsible party
- Principal investigator, Manfred Blobner, University Hospital Ulm
- Investigators
- Manfred Blobner, Professor M.D., Principal investigator, Department of Anesthesiology and Intensive Care Medicine, Ulm University Hospital, Ulm, Germany
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07829094
- Sponsor's protocol ID
- 388/24
- Acronym
- SupAIR
- Status last verified
- Sep 2026
- First submitted
- 14 Sep 2026
- Last updated
- 5 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Canet J, Hardman J, Sabate S, Langeron O, Abreu MG, Gallart L, Belda J, Markstaller K, Pelosi P, Mazo V. PERISCOPE study: predicting post-operative pulmonary complications in Europe. Eur J Anaesthesiol. 2011 Jun;28(6):459-61. doi: 10.1097/EJA.0b013e328344be2d. No abstract available.
PubMed 21544025Abbott TEF, Fowler AJ, Pelosi P, Gama de Abreu M, Moller AM, Canet J, Creagh-Brown B, Mythen M, Gin T, Lalu MM, Futier E, Grocott MP, Schultz MJ, Pearse RM; StEP-COMPAC Group. A systematic review and consensus definitions for standardised end-points in perioperative medicine: pulmonary complications. Br J Anaesth. 2018 May;120(5):1066-1079. doi: 10.1016/j.bja.2018.02.007. Epub 2018 Mar 27.
PubMed 29661384Hammer M, Santer P, Schaefer MS, Althoff FC, Wongtangman K, Frey UH, Xu X, Eikermann M, Fassbender P. Supraglottic airway device versus tracheal intubation and the risk of emergent postoperative intubation after general anaesthesia in adults: a retrospective cohort study. Br J Anaesth. 2021 Mar;126(3):738-745. doi: 10.1016/j.bja.2020.10.040. Epub 2020 Dec 17.
PubMed 33341223Abdi W, Amathieu R, Adhoum A, Poncelet C, Slavov V, Kamoun W, Combes X, Dhonneur G. Sparing the larynx during gynecological laparoscopy: a randomized trial comparing the LMA Supreme and the ETT. Acta Anaesthesiol Scand. 2010 Feb;54(2):141-6. doi: 10.1111/j.1399-6576.2009.02095.x. Epub 2009 Aug 13.
PubMed 19681772Mencke T, Echternach M, Kleinschmidt S, Lux P, Barth V, Plinkert PK, Fuchs-Buder T. Laryngeal morbidity and quality of tracheal intubation: a randomized controlled trial. Anesthesiology. 2003 May;98(5):1049-56. doi: 10.1097/00000542-200305000-00005.
PubMed 12717124Xu R, Lian Y, Li WX. Airway Complications during and after General Anesthesia: A Comparison, Systematic Review and Meta-Analysis of Using Flexible Laryngeal Mask Airways and Endotracheal Tubes. PLoS One. 2016 Jul 14;11(7):e0158137. doi: 10.1371/journal.pone.0158137. eCollection 2016.
PubMed 27414807Kirmeier E, Eriksson LI, Lewald H, Jonsson Fagerlund M, Hoeft A, Hollmann M, Meistelman C, Hunter JM, Ulm K, Blobner M; POPULAR Contributors. Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study. Lancet Respir Med. 2019 Feb;7(2):129-140. doi: 10.1016/S2213-2600(18)30294-7. Epub 2018 Sep 14.
PubMed 30224322
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Postoperative Pulmonary Complications After Use of Supraglottic Airway Devices and Neuromuscular Blockade
- ClinicalTrials.gov ID
- NCT07829094
- Acronym / sponsor ID
- SupAIR / 388/24
- Conditions
- Postoperative Pulmonary Complications
- Keywords
- Postoperative Complications, Laryngeal Masks, Intubation, Endotracheal Tube, Neuromuscular Blockade, Surgical conditions, Postoperative pulmonary complications, PPC
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 6,800 participants (estimated)
- Lead sponsor
- University Hospital UlmUniversity, hospital or other
- Collaborators
- Medical University of Vienna, Universitätsmedizin Mannheim, Klinikum Oldenburg gGmbH, University Hospital, Zürich, St. Josef Hospital Bochum
- Study start
- 15 Oct 2026 (estimated)
- Primary completion
- 1 Sep 2029 (estimated)
- Study completion
- 1 Sep 2030 (estimated)
- First posted
- 18 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
SupAIR is an international, multicenter, randomized controlled trial investigating whether airway management and neuromuscular blockade during general anesthesia influence postoperative pulmonary complications.
Approximately 6,800 adults undergoing elective non-cardiac surgery will be randomized to one of five treatment arms: tracheal intubation with moderate neuromuscular blockade, tracheal intubation with deep neuromuscular blockade, supraglottic airway with moderate neuromuscular blockade, supraglottic airway with deep neuromuscular blockade, or supraglottic airway without neuromuscular blockade.
The primary outcome is the occurrence of postoperative pulmonary complications during the hospital stay. Secondary outcomes include perioperative complications, surgical conditions, recovery, and functional health. Participants will be followed during hospitalization and again approximately six months after surgery.
Detailed description
SupAIR is an international, multicenter, randomized, controlled, parallel-group clinical trial evaluating the effects of airway management and neuromuscular blockade (NMB) on postoperative pulmonary complications after general anesthesia.
A total of 6,800 adults undergoing elective non-cardiac surgery will be randomized to one of five treatment arms:
- Tracheal tube with moderate NMB
- Tracheal tube with deep NMB
- Supraglottic airway device with moderate NMB
- Supraglottic airway device with deep NMB
- Supraglottic airway device without NMB
The five treatment arms result from an initial allocation to tracheal tube with NMB, supraglottic airway device with NMB, or supraglottic airway device without NMB. Participants assigned to NMB are additionally randomized to moderate or deep neuromuscular blockade.
The study addresses two primary hypotheses. First, among participants receiving NMB, use of a supraglottic airway device is hypothesized to reduce postoperative pulmonary complications compared with tracheal intubation. Second, among participants managed with a supraglottic airway device, the use of NMB is hypothesized not to increase postoperative pulmonary complications compared with no NMB. Finally, among participants receiving NMB depth of neuromuscular blockade will be used as secondary exposure.
The randomized intervention determines airway management and the use and depth of neuromuscular blockade. Quantitative neuromuscular monitoring is used in participants receiving NMB, and recovery from neuromuscular blockade is managed according to applicable clinical guidelines. All other aspects of perioperative anesthetic management are performed according to local clinical practice.
The primary outcome is the occurrence of at least one postoperative pulmonary complication from postoperative day 1 until hospital discharge or postoperative day 28, whichever occurs first. The composite includes respiratory failure, suspected pulmonary infection, pulmonary infiltrates, atelectasis, aspiration pneumonitis, bronchospasm, and pulmonary oedema.
Postoperative outcomes are assessed by blinded study personnel during the hospital stay. Secondary outcomes include intraoperative and postoperative complications, respiratory events in the post-anesthesia care unit, surgical conditions, quality of recovery, functional health, length of stay, intensive care treatment, and mortality. Participants are additionally followed by telephone approximately six months after surgery.
An interim analysis is planned after approximately 1,000 participants to assess assumptions relevant to sample-size planning. Interim results will be reviewed by the independent Data and Safety Monitoring Board, and the total sample size may be adjusted in accordance with the prespecified analysis plan.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 5
- Model description
- This is a randomized, controlled, parallel-group trial with three study groups. Participants are allocated to tracheal tube management with neuromuscular blockade (TT/NMB), supraglottic airway device management with neuromuscular blockade (SGA/NMB), or supraglottic airway device management without neuromuscular blockade (SGA/no NMB). Allocation occurs in an unequal ratio of 1:2.9:2.9. Patients receiving NMB are additionally allocated 1:1 to receive either deep or moderate neuromuscular blockade.
| Arm | Type | Receives |
|---|---|---|
| Tracheal Tube with moderate Neuromuscular Blockade (TT/moderate NMB) | Active comparator | Procedure: Airway management strategy, Other: Deep versus moderate neuromuscular blockade (NMB)General anesthesia with tracheal tube management and moderate neuromuscular blockade. |
| Supraglottic Airway Device with deep Neuromuscular Blockade (SGA/deep NMB) | Experimental | Procedure: Airway management strategy, Procedure: Initiation of neuromuscular blockade (NMB), Other: Deep versus moderate neuromuscular blockade (NMB)General anesthesia with supraglottic airway device management and deep neuromuscular blockade. |
| Supraglottic Airway Device without Neuromuscular Blockade (SGA/no NMB) | Active comparator | Procedure: Initiation of neuromuscular blockade (NMB)General anaesthesia with supraglottic airway device management without neuromuscular blockade. |
| Tracheal Tube with deep Neuromuscular Blockade (TT/deep NMB) | Active comparator | Procedure: Airway management strategy, Other: Deep versus moderate neuromuscular blockade (NMB)General anesthesia with tracheal tube management and deep neuromuscular blockade. |
| Supraglottic Airway Device with moderate Neuromuscular Blockade (SGA/moderate NMB) | Experimental | Procedure: Airway management strategy, Procedure: Initiation of neuromuscular blockade (NMB), Other: Deep versus moderate neuromuscular blockade (NMB)General anesthesia with supraglottic airway device management and moderate neuromuscular blockade. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Adult patients (≥ 18 years) with an ASA physical status ≤ 3 scheduled for elective non-cardiac surgery under general anaesthesia whose airway can be secured via tracheal tube or SGA.
Key exclusion criteria (1 listed)
- Contraindications for using supraglottic devices, tracheal tube, or neuromuscular blocking agents (and reversal drugs); surgery in prone positioning; surgical procedures scheduled outside the operating room; ambulatory surgery; pregnancy; patients planned for consecutive anaesthetic/surgical procedures in the following 14 days or within the past 14 days.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Airway management strategyFor the superiority hypothesis the placement of the supraglottic airway device compared to the endotracheal tube is investigated. | Procedure or surgery | Supraglottic Airway Device with deep Neuromuscular Blockade (SGA/deep NMB), Supraglottic Airway Device with moderate Neuromuscular Blockade (SGA/moderate NMB), Tracheal Tube with deep Neuromuscular Blockade (TT/deep NMB), Tracheal Tube with moderate Neuromuscular Blockade (TT/moderate NMB) |
| Initiation of neuromuscular blockade (NMB)For the non-inferiority hypothesis the initiation of neuromuscular blockade in patients receiving a supraglottic airway is investigated. | Procedure or surgery | Supraglottic Airway Device with deep Neuromuscular Blockade (SGA/deep NMB), Supraglottic Airway Device with moderate Neuromuscular Blockade (SGA/moderate NMB), Supraglottic Airway Device without Neuromuscular Blockade (SGA/no NMB) |
| Deep versus moderate neuromuscular blockade (NMB)Deep or moderate NMB. Muscle relaxants are administered according to group allocation. Repetitive doses of half the ED95s are administered at Train-of-Four (TOF) count ≥ 2 in the moderate group and at post-tetanic count (PTC) ≥ 2 in the deep blockade group. | Other | Supraglottic Airway Device with deep Neuromuscular Blockade (SGA/deep NMB), Supraglottic Airway Device with moderate Neuromuscular Blockade (SGA/moderate NMB), Tracheal Tube with deep Neuromuscular Blockade (TT/deep NMB), Tracheal Tube with moderate Neuromuscular Blockade (TT/moderate NMB) |
Primary outcome
Occurrence of at least one postoperative pulmonary complication
Time frame: Postoperative day one until hospital discharge or postoperative day 28, whichever occurs earlier
The primary outcome is a composite endpoint of postoperative pulmonary complications. It is met if a participant experiences at least one predefined postoperative pulmonary complication and their severity is graded according to the Clavien-Dindo-Classification
7 secondary outcomes
Intraoperative complications
Time frame: During the surgery
Critical respiratory events in the recovery room
Time frame: During post-anesthesia care before admission to the normal ward
Any postoperative in-hospital complication
Time frame: Patients are visited on postoperative days 1 and 3 to 4 in person and on the day of discharge from hospital or day 28 (whatever occurs first) via chart review to document complications between the current and the last assessment.
Surgical conditions
Time frame: During surgery, assessed every 15 minutes
Quality of Recovery questionnaire
Time frame: On postoperative day 1, day of discharge or on day 28 whatever occurs first and on postoperative day 180
Functional Health
Time frame: During pre-admission testing and 180 days after surgery
Further Outcomes
Time frame: Retrieved from Chart Review or at the 180 day follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2026.
- Background: PubMed 21544025Canet J, Hardman J, Sabate S, Langeron O, Abreu MG, Gallart L, Belda J, Markstaller K, Pelosi P, Mazo V. PERISCOPE study: predicting post-operative pulmonary complications in Europe. Eur J Anaesthesiol. 2011 Jun;28(6):459-61. doi: 10.1097/EJA.0b013e328344be2d. No abstract available.
- Background: PubMed 29661384Abbott TEF, Fowler AJ, Pelosi P, Gama de Abreu M, Moller AM, Canet J, Creagh-Brown B, Mythen M, Gin T, Lalu MM, Futier E, Grocott MP, Schultz MJ, Pearse RM; StEP-COMPAC Group. A systematic review and consensus definitions for standardised end-points in perioperative medicine: pulmonary complications. Br J Anaesth. 2018 May;120(5):1066-1079. doi: 10.1016/j.bja.2018.02.007. Epub 2018 Mar 27.
- Background: PubMed 33341223Hammer M, Santer P, Schaefer MS, Althoff FC, Wongtangman K, Frey UH, Xu X, Eikermann M, Fassbender P. Supraglottic airway device versus tracheal intubation and the risk of emergent postoperative intubation after general anaesthesia in adults: a retrospective cohort study. Br J Anaesth. 2021 Mar;126(3):738-745. doi: 10.1016/j.bja.2020.10.040. Epub 2020 Dec 17.
- Background: PubMed 19681772Abdi W, Amathieu R, Adhoum A, Poncelet C, Slavov V, Kamoun W, Combes X, Dhonneur G. Sparing the larynx during gynecological laparoscopy: a randomized trial comparing the LMA Supreme and the ETT. Acta Anaesthesiol Scand. 2010 Feb;54(2):141-6. doi: 10.1111/j.1399-6576.2009.02095.x. Epub 2009 Aug 13.
- Background: PubMed 12717124Mencke T, Echternach M, Kleinschmidt S, Lux P, Barth V, Plinkert PK, Fuchs-Buder T. Laryngeal morbidity and quality of tracheal intubation: a randomized controlled trial. Anesthesiology. 2003 May;98(5):1049-56. doi: 10.1097/00000542-200305000-00005.
- Background: PubMed 27414807Xu R, Lian Y, Li WX. Airway Complications during and after General Anesthesia: A Comparison, Systematic Review and Meta-Analysis of Using Flexible Laryngeal Mask Airways and Endotracheal Tubes. PLoS One. 2016 Jul 14;11(7):e0158137. doi: 10.1371/journal.pone.0158137. eCollection 2016.
- Background: PubMed 30224322Kirmeier E, Eriksson LI, Lewald H, Jonsson Fagerlund M, Hoeft A, Hollmann M, Meistelman C, Hunter JM, Ulm K, Blobner M; POPULAR Contributors. Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study. Lancet Respir Med. 2019 Feb;7(2):129-140. doi: 10.1016/S2213-2600(18)30294-7. Epub 2018 Sep 14.
- Individual participant dataSharing planned: No
Related trials for Postoperative Pulmonary Complications
Not yet recruiting
Individualized Inspired Oxygen Fraction Titration During Lung Surgery (iOXY-LUNG)
Postoperative Complications
Active, not recruitingObservational study
The Effect of Single Lung Ventilation Duration and Intraoperative Brain Oxygenation on Cognitive Function and Postoperative Pain in Geriatric Patients
Thoracic Anesthesia, Geriatric Anesthesia
Not yet recruitingObservational study
Diaphragm Ultrasound and Neuromuscular Monitoring for Predicting Early Respiratory Events After Extubation
Residual Neuromuscular Blockade, Diaphragm Dysfunction
Recruiting
Uncovering the Mechanism of Pain Relief by Peripheral Transcutaneous Magnetic Stimulation
Post-Surgical Pain, Chronic, Post-traumatic Pain, Chronic
Not yet recruiting
Low-Dose Norepinephrine With Conservative Fluid Therapy in Hepatobiliary Surgery
Postoperative Complications, Pulmonary Complication
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Béla-Simon Paschold, M.D. Coordinating Investigator contact
Clinical Research Physician contact
Manfred Blobner, Professor M.D. principal investigator
Department of Anesthesiology and Intensive Care Medicine, Ulm University Hospital, Ulm, Germany
Questions about this trial
What is this clinical trial studying?
A study testing Airway management strategy, Initiation of neuromuscular blockade (NMB) and Deep versus moderate neuromuscular blockade (NMB) in people with Postoperative Pulmonary Complications, run by University Hospital Ulm.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Béla-Simon Paschold, M.D. Coordinating Investigator (+49 731 50060390, bela-simon.paschold@uni-ulm.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Occurrence of at least one postoperative pulmonary complication (time frame: Postoperative day one until hospital discharge or postoperative day 28, whichever occurs earlier). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07829094, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2026.